Real-World Study of Subcutaneous Methotrexate Treatment in Chinese Adults with Rheumatoid Arthritis and Related Conditions

What this Trial Is About

Researchers are evaluating the use of subcutaneous Methotrexate MTX in adult Chinese patients with rheumatoid arthritis RA to study its effectiveness and safety in a real-world setting. The study also explores MTXs effects in RA patients who have additional conditions such as interstitial lung disease ILD, interstitial lung abnormalities ILAs, or stable coronary artery disease SCAD, and investigates different clinical subtypes of RA. This observational study will include large groups of patients divided by these conditions to better understand treatment outcomes. Participants receive subcutaneous MTX as part of their usual care without interference from the study. The study organizes patients into four cohorts general RA patients receiving MTX, those with ILD or ILAs, those with known clinical subtype results, and patients with SCAD. Treatment follows the standard clinical plan, and the study observes how patients respond over time while continuing their regular treatment routines. During the study, participants will be monitored at 4, 12, and 24 weeks after starting MTX treatment. Researchers will assess response rates using ACR205070 criteria, disease activity scores DAS28 and CDAI, and patient and evaluator assessments for pain and overall health. Safety is also tracked by recording adverse events and drug reactions. The study aims to gather detailed data on both the benefits and risks of subcutaneous MTX in routine clinical practice, with participation lasting at least 24 weeks.

A RWS of SC MTX in Chinese RA Patients